Skip to main content
    E

    Electrocore LLC (ECOR)

    Official site

    HEALTHCARE • MEDICAL DEVICES • NASDAQ

    $4.84
    -0.41 (-7.81%)

    Market Cap: $48.44M

    Last updated: Nov 17, 2026 at 11:02 AM ET

    Electrocore LLC (ECOR) Earnings: Report Dates and Results

    Updated Nov 4, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    Electrocore LLC (ECOR) is expected to report earnings on Mar 17, 2027. In the quarter ended Sep 30, 2026, Electrocore LLC reported EPS of -$0.13, above the -$0.26 estimate. It beat the EPS estimate in 4 of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    50%(17/34)
    Avg Surprise
    +2.36%
    Streak
    4 Q

    Upcoming Estimates

    Reports Mar 17, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus-$0.21
    Range-$0.25 - -$0.14
    7 analysts
    Revenue Consensus
    $11.55M
    Range$10.69M - $12.31M
    7 analysts
    Reports May 4, 2027 (est.)Period ending Mar 31, 2027
    EPS Consensus-$0.14
    Range-$0.20 - -$0.05
    4 analysts
    EPS Revisions
    0
    1
    30d
    EPS Estimate DriftChange to current
    90d ago-$0.35+61.1%
    60d ago-$0.34+59.7%
    30d ago-$0.34+59.7%
    7d ago-$0.34+59.7%
    Current-$0.14
    Revenue Consensus
    $12.04M
    Range$11.50M - $12.40M
    4 analysts

    Next Report

    ECOR has an expected report date of Mar 17, 2027.

    ECOR Earnings Call

    The latest ECOR earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    Earnings History

    Of the 34 quarters below that had an estimate, ECOR beat 17, missed 15 and matched 2. Revenue for the quarter ended Sep 30, 2026 was $9.69M, up 11.5% from $8.69M a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026-$0.13-$0.26-$0.31 - -$0.23+50.00%BeatN/A53 up, 1 downNov 4, 2026$9.69M
    Jun 30, 2026-$0.33-$0.41-$0.50 - -$0.31+19.51%BeatN/A50 up, 1 downAug 6, 2026$9.45M
    Mar 31, 2026-$0.59-$0.61-$0.68 - -$0.52+3.28%BeatN/A40 up, 4 downMay 6, 2026$9.58M
    Dec 31, 2025-$0.34-$0.39-$0.46 - -$0.30+13.38%BeatN/A41 up, 1 downMar 19, 2026$9.24M
    Sep 30, 2025-$0.40-$0.36-$0.45 - -$0.35-11.11%MissN/A50 up, 0 downNov 5, 2025$8.69M
    Jun 30, 2025-$0.44-$0.32N/A-37.50%MissN/AN/A0 up, 0 downAug 6, 2025$7.38M
    Mar 31, 2025-$0.47-$0.45N/A-4.44%MissN/AN/A0 up, 0 downMay 7, 2025$6.72M
    Dec 31, 2024-$0.40-$0.34N/A-17.65%MissN/AN/A0 up, 0 downMar 12, 2025$7.05M
    Sep 30, 2024-$0.31-$0.33-$0.36 - -$0.30+6.06%BeatN/A30 up, 0 downNov 13, 2024$6.55M
    Jun 30, 2024-$0.38-$0.43-$0.48 - -$0.37+11.63%BeatN/A40 up, 0 downAug 7, 2024$6.14M
    Mar 31, 2024-$0.53-$0.59-$0.70 - -$0.54+10.17%BeatN/A40 up, 0 downMay 8, 2024$5.44M
    Dec 31, 2023-$0.61-$0.61-$0.63 - -$0.570.00%In lineN/A40 up, 0 downMar 13, 2024$5.19M
    Sep 30, 2023-$0.68-$0.79-$0.84 - -$0.51+13.92%BeatN/A60 up, 0 downNov 8, 2023$4.51M
    Jun 30, 2023-$1.02-$0.93-$1.11 - -$0.70-9.68%MissN/A64 up, 1 downAug 9, 2023$3.55M
    Mar 31, 2023-$1.17-$0.99-$1.19 - -$0.61-18.18%MissN/A51 up, 0 downMay 3, 2023$2.78M
    Dec 31, 2022-$1.22-$1.12-$1.20 - -$1.03-8.93%MissN/A51 up, 0 downMar 8, 2023$2.56M
    Sep 30, 2022-$1.20-$1.05-$1.35 - -$0.90-14.29%MissN/A51 up, 0 downNov 3, 2022$1.98M
    Jun 30, 2022-$1.20-$1.05-$1.20 - -$0.90-14.29%MissN/A50 up, 0 downAug 4, 2022$2.16M
    Mar 31, 2022-$1.17-$1.05-$1.35 - -$0.75-11.43%MissN/A50 up, 0 downMay 5, 2022$1.90M
    Dec 31, 2021-$1.05-$1.02-$1.05 - -$0.90-2.94%MissN/A60 up, 0 downMar 10, 2022$1.49M
    Sep 30, 2021-$0.90-$1.20-$1.50 - -$1.05+25.00%BeatN/A6N/ANov 4, 2021$1.49M
    Jun 30, 2021-$1.19-$1.72-$1.80 - -$1.65+30.81%BeatN/A5N/AAug 5, 2021$1.27M
    Mar 31, 2021-$1.65-$1.69-$1.80 - -$1.50+2.37%BeatN/A4N/AMay 6, 2021$1.20M
    Dec 31, 2020-$2.10-$1.56-$1.80 - -$1.20-34.62%MissN/A5N/AMar 11, 2021$928265
    Sep 30, 2020-$1.50-$1.87-$2.70 - -$1.50+19.79%BeatN/A6N/ANov 12, 2020$1.08M
    Jun 30, 2020-$1.95-$2.95N/A+33.90%BeatN/A3N/AAug 13, 2020$752955
    Mar 31, 2020-$4.05-$3.45-$3.75 - -$3.15-17.39%MissN/A2N/AMay 14, 2020$733771
    Dec 31, 2019-$4.35-$4.35-$4.80 - -$3.300.00%In lineN/A4N/AMar 23, 2020$674942
    Sep 30, 2019-$4.89-$7.50N/A+34.80%BeatN/A4N/ANov 13, 2019$682993
    Jun 30, 2019-$5.75-$7.12-$7.35 - -$5.85+19.24%BeatN/A3N/AAug 13, 2019$622743
    Mar 31, 2019-$7.05-$6.45N/A-9.30%MissN/A3N/AMay 14, 2019$409601
    Dec 31, 2018-$7.95-$8.00-$9.60 - -$7.05+0.63%Beat-39850.0%3N/AMar 28, 2019$367568
    Sep 30, 2018-$6.75-$5.70-$8.85 - -$4.80-18.42%MissN/A3N/ANov 13, 2018$150972
    Jun 30, 2018-$3.15-$3.75-$7.80 - -$3.75+16.00%BeatN/A2N/AAug 13, 2018$393226
    Mar 31, 2018-$0.38N/AN/AN/AN/AN/AN/AN/AJun 25, 2018$81187
    Dec 31, 2017$0.02N/AN/AN/AN/AN/AN/AN/AMar 30, 2018$234730
    Last 36 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was -$1.65, after -$1.62 the year before. It was $0.02 for the year ended Dec 31, 2017, the oldest of the 9 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025-$1.65N/A
    Dec 31, 2024-$1.62N/A
    Dec 31, 2023-$3.48N/A
    Dec 31, 2022-$4.79N/A
    Dec 31, 2021-$4.79N/A
    Dec 31, 2020-$9.60N/A
    Dec 31, 2019-$22.04N/A
    Dec 31, 2018-$18.23-91225.0%
    Dec 31, 2017$0.02N/A

    Earnings Calls

    The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 8,300 words across 10 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q3Sep 30, 20268,29210
    2026Q1Mar 31, 20267,1198
    2025Q4Dec 31, 20254,4557
    2025Q3Sep 30, 20256,1788
    2025Q2Jun 30, 20254,1175
    2025Q1Mar 31, 20255,4145
    2024Q4Dec 31, 20247,6456
    2024Q3Sep 30, 20244,8735

    2026Q3 Earnings Call

    Opening remarks

    Thomas Errico Founder and Independent Chairman Thank you, operator. Good afternoon, everyone, and thank you for joining electroCore's Third Quarter 2026 Earnings Call. This quarter was about strengthening the foundation, leadership, commercial execution and regulatory clarity. The results strengthen my conviction and excitement about the company's current trajectory. This was a record quarter for electroCore, our highest net sales and our smallest operating loss in company history. Behind those results, management is building a commercial organization designed to grow profitably at a much larger scale. As with any transformation, the changes have been significant, and we believe the changes we have executed have established a foundation that positions electroCore for accelerated growth and an inflection point in positive adjusted EBITDA in 2027. For me, one of the most exciting developments is our progress opening new markets. On October 27, we filed our 510(k) premarket notification with the FDA seeking clearance for our Quell wearable neurostimulation device for the treatment of chemotherapy-induced peripheral neuropathy, or CIPN. This submission comes on the back of the breakthrough designation from the FDA in January 2022, which covers the reduction of moderate to severe symptoms of chemotherapy-induced peripheral neuropathy that have persisted for at least six months after chemotherapy ended. If cleared, Quell could offer a new nondrug option for patients experiencing CIPN, an important step for electroCore and those patients looking for symptom relief. Combined with continued progress in commercial execution and financial discipline, this new opportunity shows the path forward is stronger today than at any point in the last several years. Josh will take you through the quarter and where we are headed. Mike will walk you through the plans implemented for growth and measures we track in the field, and Josh will then return with the financials. Josh?

    Joshua Lev Co-Chief Executive Officer, President and Chief Financial Officer Thank you, Tom. Good afternoon, everyone. This quarter, we delivered record net sales of $9.7 million, up approximately 12% from a year ago, and the lowest operating loss in our history, with adjusted EBITDA loss improving by nearly $1.4 million in the quarter, ahead of our expectations. Gross margin expanded to 88.5% and loss from operations narrowed to $1.6 million. GAAP net loss improved by $1.3 million, or $0.13 per share, from $3.1 million, or $0.33 per share, in the second quarter, and adjusted EBITDA loss improved to a company record $700,000. We grew revenue while spending less to do it. I will take you through the full financials later in the call. I want to be direct about where we are taking this company. We are not managing for short-term gains. We are building long-term revenue that is durable, repeatable and profitable.

    Frequently Asked Questions About ECOR

    When is Electrocore LLC's next earnings date?

    Electrocore LLC's next earnings report is expected for Mar 17, 2027.

    Did ECOR beat earnings estimates last quarter?

    Yes. Electrocore LLC reported EPS of -$0.13 for the quarter ended Sep 30, 2026, above the -$0.26 estimate, a 50.00% surprise.

    What EPS do analysts expect from ECOR next quarter?

    The consensus EPS estimate for Electrocore LLC for the quarter ending Dec 31, 2026 is -$0.21 from 7 analysts, with estimates from -$0.25 to -$0.14.

    How often does ECOR beat earnings estimates?

    Electrocore LLC beat the EPS estimate in 4 of the last 8 quarters, with an average surprise of +1.93%.